INTRODUCTION
============

Breast cancer is one of most common cancers in women and comprises about 23% of all female carcinomas.[@B1] With regard to histologic subtypes, invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the major two subtypes of invasive carcinoma of the breast.[@B1] Among the various subtypes, ILC accounts for about 5-15% of all invasive carcinomas,[@B2],[@B3] and the incidence of ILC has increased more rapidly than that of IDC in the past decade due to widely-prescribed hormone replacement therapy and increasing alcohol consumption.[@B4],[@B5] ILC is distinguished from IDC by several clinical and histologic features. For example, ILC usually shows multifocal manifestation and tends to occur in both breasts simultaneously.[@B6],[@B7] Histologically, ILC is characterized by discohesive cancer cells lacking E-cadherin expression.[@B8] Metastatic sites in ILC are often unusual regions including the bones, gastrointestinal tract, uterus, meninges, and ovaries, which are rarely involved in cases of IDC.[@B7],[@B9],[@B10]

Sarcosine (N-methylglycine) is a non-proteinogenic amino acid that is made during the metabolism and catabolism of glycine. Several major enzymes involved in the sarcosine metabolism pathway include glycine *N*-methyltransferase (GNMT), sarcosine dehydrogenase (SARDH), and l-pipecolic acid oxidase (PIPOX). GNMT participates in the production of sarcosine by transmitting the methyl group from S-adenosylmethionine to glycine. SARDH and PIPOX, both sarcosine-metabolizing enzymes, produce glycine from sarcosine by oxidative demethylation.[@B11] Sarcosine has been reported as a potential oncometabolite more than non-proteinogenic amino acid. In prostate cancer, sarcosine was studied as a sensitive tumor biomarker and was also found to have a relationship with tumor progression and the metastatic process.[@B12],[@B13] Like prostate cancer, breast cancer is hormone-dependent cancer, although in this case, it is predominantly related to estrogen receptor (ER) and progesterone receptor (PR). However, androgen receptor (AR) is also expressed in breast cancer, especially in ILC.[@B14] In contrast, the expression of sarcosine metabolism-related proteins in breast cancer remains to be elucidated. We aimed to investigate the expression of sarcosine metabolism-related proteins in ILC and IDC, to compare the expression rates in ILC and IDC, and to determine the implications of the results.

MATERIALS AND METHODS
=====================

Patient selection and clinicopathologic evaluation
--------------------------------------------------

Between January 2000 and December 2012, formalin-fixed, paraffin-embedded (FFPE) tissue samples were collected at Severance Hospital. Tissue samples were obtained from patients who had undergone breast surgery due to ILC. For the control group, tissue samples were prepared from patients diagnosed with IDC, not otherwise specified from 2006 to 2010. This study was approved by the Institutional Review Board of Severance Hospital. Patients who had received preoperative chemotherapy were excluded from this study. Histologic examination was performed by hematoxylin and eosin (H&E) staining, and all slides were reviewed retrospectively by a trained breast pathologist (Koo JS). The histologic grade was assessed using the Nottingham grading system.[@B15] Tumor staging was based on the seventh American Joint Committee on Cancer criteria. Disease-free survival was calculated from the date of the first curative surgery to the date of the first loco-regional or systemic relapse or to death without any type of relapse. Overall survival was estimated from the date of the first curative operation to the date of the last follow-up or death from any cause. Clinicopathologic parameters evaluated in each type of breast cancer included patient age at initial diagnosis, lymph node metastasis, tumor recurrence, distant metastasis, and patient survival.

Tissue microarray
-----------------

Through retrospective review of the H&E-stained slides, the most appropriate FFPE tumor tissue samples were retrieved, and representative tumor areas were circled on the FFPE blocks. Two 3.0-mm tissue cores were taken from the representative region of each paraffin block and inserted into 6×5 recipient blocks.

Immunohistochemistry
--------------------

The antibodies used for immunohistochemistry in this study are shown in [Table 1](#T1){ref-type="table"}. Three-micrometer paraffin sections were deparaffinized and rehydrated by xylene and alcohol solution. Immunohistochemistry was performed using a Ventana Discovery XT automated staining system (Ventana Medical System, Tucson, AZ, USA). Antigen retrieval was performed using CC1 buffer \[Cell Conditioning 1; citrate buffer (pH 6.0), Ventana Medical System\]. Appropriate positive and negative controls for immunohistochemical staining were also included.

Interpretation of immunohistochemical results
---------------------------------------------

A cut-off value of 1% or more positively-stained nuclei was used to define ER and AR positivity.[@B16] Human epidermal growth factor receptor-2 (HER-2) staining was analyzed according to the American Society of Clinical Oncology/College of American Pathologists guidelines using the following categories: 0=no immunostaining; 1+=weak incomplete membranous staining in less than 10% of tumor cells; 2+=complete membranous staining either uniform or weak in at least 10% of tumor cells; and 3+=uniform intense membranous staining in at least 30% of tumor cells.[@B17] HER-2 immunostaining was considered positive when strong (3+) membranous staining was observed whereas cases with 0 to 1+ staining were regarded as negative. The cases showing 2+ HER-2 expression were evaluated for HER-2 amplification by fluorescent *in situ* hybridization (FISH).

Immunohistochemical markers for GNMT, SARDH, and PIPOX were accessed by light microscopy. Interpretation of immunohistochemical staining for autophagy and redox-related proteins was determined by multiplying the proportion of stained cells (0%=0; 1-29%=1; 30-100%=2) by the immunostaining intensity (negative=0; weak=1; moderate=2; strong=3). Final scores of 0-1 were interpreted as negative, and scores of 2-6 were considered positive.[@B18] The Ki-67 labeling index (LI) was scored by percentage of nuclear stained cells in total tumor cells (0-100%).

Tumor phenotype classification
------------------------------

In this study, we classified breast cancer phenotypes according to the immunohistochemistry results for ER, PR, HER-2, and Ki-67 LI. FISH results for HER-2 were classified as follows:[@B19] luminal A type: ER and/or PR positive, HER-2 negative, and Ki-67 LI\<14%; luminal B type: (HER-2 negative) ER and/or PR positive, HER-2 negative, and Ki-67 LI≥14% and (HER-2 positive) ER and/or PR positive and HER-2 overexpressed or amplified; HER-2 type: ER and PR negative and HER-2 overexpressed or amplified; triple-negative breast cancer (TNBC) type: ER, PR, and HER-2 negative.

Sarcosine metabolism phenotypes
-------------------------------

According to immunohistochemistry results for GNMT, SARDH, and PIPOX, sarcosine metabolism phenotypes were categorized as follows: high sarcosine type: GNMT (+), SARDH and PIPOX (-); low sarcosine type: GNMT (-), SARDH and/or PIPOX (+); intermediate sarcosine type: GNMT (+), SARDH or PIPOX (+); and null type: GNMT (-), SARDH and PIPOX (-).

Statistical analysis
--------------------

Data were statistically processed using SPSS for Windows version 12.0 (SPSS Inc., Chicago, IL, USA). Student\'s t-test and Fisher\'s exact test were used for continuous and categorical variables, respectively. Statistical significance was assumed when *p*\<0.05. Kaplan-Meier survival curves and log-rank statistics were employed to evaluate time to survival. Multivariate regression analysis was performed using the Cox proportional hazards model.

RESULTS
=======

Basal characteristics of invasive lobular carcinoma
---------------------------------------------------

The clinicopathologic characteristics of patients with ILC are summarized in [Table 2](#T2){ref-type="table"}. There were 114 patients with ILC, subdivided into 102 classic-type and 12 pleomorphic-type patients. The pleomorphic type showed significant association with older age (*p*=0.033), a higher nuclear grade (*p*\<0.001), a higher histologic grade (*p*\<0.001), a higher T stage (*p*=0.026), PR negativity (*p*=0.005), HER-2 positivity (*p*=0.002), a higher Ki-67 LI (*p*\<0.001), and the non-luminal A subtype (*p*\<0.001) compared with the classic type.

When comparing clinicopathologic parameters of ILC with those of IDC, ILC was associated with a lower histologic grade (*p*\<0.001), no lymph node metastasis (*p*=0.026), ER positivity (*p*\<0.001), PR positivity (*p*\<0.001), HER-2 negativity (*p*\<0.001), a lower Ki-67 LI (*p*\<0.001), and a higher incidence of luminal A type (*p*\<0.001) ([Table 3](#T3){ref-type="table"}).

Expression of sarcosine metabolism-related proteins in normal tissue, ILC, and IDC
----------------------------------------------------------------------------------

No difference was observed in the expression of sarcosine metabolism-related proteins between the subtypes of ILC, although expressions of SARDH and PIPOX were higher in ILC compared to normal tissue (SARDH: *p*=0.014; PIPOX: *p*\<0.001) ([Table 4](#T4){ref-type="table"}). When comparing ILC with IDC, ILC showed a higher expression of PIPOX (*p*\<0.001) ([Table 5](#T5){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}). This difference of expression was also observed between ILC and IDC luminal types (*p*\<0.001) ([Table 6](#T6){ref-type="table"}).

Comparison of sarcosine metabolism phenotypes among normal tissue, IDC, and ILC
-------------------------------------------------------------------------------

Sarcosine metabolic phenotypes based on the expression of sarcosine metabolism-related proteins showed different distributions among normal breast tissue, IDC, and ILC ([Table 7](#T7){ref-type="table"}). Sarcosine metabolic phenotypes of normal breast tissue were null type (93.3%) and low sarcosine type (6.7%). In IDC, sarcosine metabolic phenotypes were composed of null type (61.7%)\>low sarcosine type (30.4%)\>high sarcosine type (5.0%)\>intermediate type (2.9%); however, in ILC, the proportion of sarcosine metabolic phenotypes was low sarcosine type (61.4%)\>null type (32.5%)\>intermediate type (5.3%)\>high sarcosine type (0.9%) (*p*\<0.001). These different distributions of sarcosine metabolic phenotypes between IDC and ILC were sustained when compared with the sarcosine metabolic phenotypes in luminal-type IDC (*p*\<0.001) ([Table 8](#T8){ref-type="table"}).

Correlation between sarcosine metabolism-related proteins and clinicopathologic factors in ILC
----------------------------------------------------------------------------------------------

In ILC, PIPOX expression was correlated with AR positivity (*p*=0.001) ([Fig. 2](#F2){ref-type="fig"}). In the classical type, PIPOX expression was also correlated with AR positivity (*p*=0.003), and SARDH expression was associated with a higher T stage (*p*=0.004). In the pleomorphic type, SARDH expression was correlated with a higher Ki-67 LI (*p*=0.018) and associated with the luminal A molecular type. All SARDH-positive cases were luminal A molecular type, and all SARDH-negative cases were non-luminal A molecular type (*p*=0.007).

Impact of expression status for sarcosine metabolism-related proteins on prognosis in ILC
-----------------------------------------------------------------------------------------

In ILC, no significant association was found between metabolism-related proteins and prognosis with univariate analysis ([Table 9](#T9){ref-type="table"}).

DISCUSSION
==========

The purpose of the present study was to investigate and compare the expressions of sarcosine metabolism-related proteins in ILC and IDC. Compared to IDC, PIPOX had a higher expression rate in ILC (*p*\<0.001). Sarcosine metabolic phenotypes, based on expressions of sarcosine metabolism-related proteins, were found to have different proportional distributions between ILC and IDC. Low sarcosine type was most common in ILC, whereas null type was most common in IDC. In the present study, sarcosine metabolism-related proteins and sarcosine metabolic phenotypes were different in ILC and IDC, and there were also clinical and histologic distinctions found between ILC and IDC. Although expressions of sarcosine metabolism-related proteins are not yet well-studied in breast cancer, an increased sarcosine level has been associated with cancer progression in prostate cancer. The addition of exogenous sarcosine was reported to induce invasive phenotypes in benign prostate lesions,[@B11] and elevated sarcosine levels in prostate cancer have also been found.[@B20] Also, sarcosine elevation is known to be associated with prostate cancer growth and progression *in vitro* and *in vivo*.[@B12] Different sarcosine metabolism-related proteins and sarcosine metabolic phenotypes in ILC and IDC could result in different tumor biology and behavior between ILC and IDC, as sarcosine has been reported to affect to tumor biology in prostate cancer, although further investigation is required in breast cancer.

In the present study, sarcosine metabolism-related proteins (GNMT, SARDH, and PIPOX) were evaluated instead of sarcosine level measurements in breast cancer tissue. In a prior study, sarcosine levels in prostate cancer tissue were well-correlated with elevated GNMT (a sarcosine-generating enzyme) and reduced SARDH and PIPOX, both of which are sarcosine-metabolizing enzymes.[@B12] Considering that ILC in the present study had a higher PIPOX expression rate and more of the low sarcosine phenotype than other types, we expect that a reduced sarcosine level may be found in ILC. However, further validation is needed.

Meanwhile, most of ILC is of the luminal type in molecular classification, whereas IDC is composed of HER-2 and basal-like types, addition to luminal type. In contrast to luminal-type IDC, ILC persistently had a higher PIPOX expression rate and a larger proportion of the low sarcosine phenotype. Thus, in spite of differences of composition of molecular subtypes between ILC and IDC, sarcosine metabolism in ILC and IDC may be unrelated to molecular subtype. In the present study, expression of PIPOX in ILC was correlated with AR positivity (*p*=0.001), which is incompatible with the previous study on prostate cancer that showed correlation with GNMT expression and AR positivity.[@B21] This discordance may originate from organ-specific differences; therefore, further study on AR and sarcosine metabolism in ILC is required.

In conclusion, ILC and IDC exhibited different expressions of sarcosine metabolism-related proteins. The low sarcosine type comprised the majority of ILC, and PIPOX expression was dominant in ILC.
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###### Source, Clone, and Dilution of Antibodies Used in This Study

![](ymj-56-598-i001)

  Antibody                       Company                                 Clone        Dilution
  ------------------------------ --------------------------------------- ------------ ----------
  Sarcosine metabolism-related                                                        
   GNMT                          Abcam, Cambridge, UK                    Polyclonal   1:100
   SARDH                         Abcam, Cambridge, UK                    Polyclonal   1:100
   PIPOX                         Abcam, Cambridge, UK                    Polyclonal   1:100
  Molecular subtype-related                                                           
   ER                            Thermo Scientific, San Siego, CA, USA   SP1          1:100
   PR                            DAKO, Glostrup, Denmark                 PgR          1:50
   HER-2                         DAKO, Glostrup, Denmark                 Polyclonal   1:1500
   Ki-67                         Abcam, Cambridge, UK                    MIB          1:1000
  Androgen-related                                                                    
   AR                            DAKO, Glostrup, Denmark                 AR441        1:150

GNMT, glycine *N*-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; HER-2, human epidermal growth factor receptor-2.

###### Clinicopathologic Characteristics of Invasive Lobular Carcinoma

![](ymj-56-598-i002)

  Parameters              Total, n=114 (%)   Classic type, n=102 (%)   Pleomorphic type, n=12 (%)   *p* value
  ----------------------- ------------------ ------------------------- ---------------------------- -----------
  Age (yrs)                                                                                         0.033
   \<50                   63 (55.3)          60 (58.8)                 3 (25.0)                     
   ≥50                    51 (44.7)          42 (41.2)                 9 (75.0)                     
  Nuclear grade                                                                                     \<0.001
   1/2                    102 (89.5)         102 (100.0)               0 (0.0)                      
   3                      12 (10.5)          0 (0.0)                   12 (100.0)                   
  Histologic grade                                                                                  \<0.001
   I/II                   109 (95.6)         102 (100.0)               7 (58.3)                     
   III                    5 (4.4)            0 (0.0)                   5 (41.7)                     
  T stage                                                                                           0.026
   T1                     67 (58.8)          64 (62.7)                 3 (25.0)                     
   T2/T3                  47 (41.2)          38 (37.3)                 9 (75.0)                     
  Lymph node metastasis                                                                             0.749
   Absent                 80 (70.2)          72 (70.6)                 8 (66.7)                     
   Present                34 (29.8)          30 (29.4)                 4 (33.3)                     
  ER                                                                                                0.158
   Negative               7 (6.1)            5 (4.9)                   2 (16.7)                     
   Positive               107 (93.9)         97 (95.1)                 10 (83.3)                    
  PR                                                                                                0.005
   Negative               19 (16.7)          13 (12.7)                 6 (50.0)                     
   Positive               95 (83.3)          89 (87.3)                 6 (50.0)                     
  HER-2                                                                                             0.002
   Negative               107 (93.9)         99 (97.1)                 8 (66.7)                     
   Positive               7 (6.1)            3 (2.9)                   4 (33.3)                     
  AR                                                                                                0.515
   Negative               48 (42.1)          44 (43.1)                 4 (33.3)                     
   Positive               66 (57.9)          58 (56.9)                 8 (66.7)                     
  Ki-67 LI                                                                                          \<0.001
   ≤14                    92 (80.7)          88 (86.3)                 4 (33.3)                     
   \>14                   22 (19.3)          14 (13.7)                 8 (66.7)                     
  Molecular type                                                                                    \<0.001
   Luminal A              86 (75.4)          83 (81.4)                 3 (25.0)                     
   Luminal B              22 (19.3)          15 (14.7)                 7 (58.3)                     
   HER-2                  1 (0.9)            0 (0.0)                   1 (8.3)                      
   TNBC                   5 (4.4)            4 (3.9)                   1 (8.3)                      

ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; LI, labeling index; HER-2, human epidermal growth factor receptor-2; TNBC, triple-negative breast cancer.

###### Comparison of Clinicopathologic Characteristics between Invasive Lobular Carcinoma and Invasive Ductal Carcinoma

![](ymj-56-598-i003)

  Parameters              Total, n=835 (%)   IDC, n=721 (%)   ILC, n=114 (%)   *p* value
  ----------------------- ------------------ ---------------- ---------------- -----------
  Age (yrs)                                                                    0.832
   \<50                   491 (58.8)         428 (59.4)       63 (55.3)        
   ≥50                    344 (41.2)         293 (40.6)       51 (44.7)        
  Histologic grade                                                             \<0.001
   I/II                   594 (71.1)         485 (67.3)       109 (95.6)       
   III                    241 (28.9)         236 (32.7)       5 (4.4)          
  T stage                                                                      0.058
   T1                     422 (50.5)         355 (49.2)       67 (58.8)        
   T2/T3                  413 (49.5)         366 (50.8)       47 (41.2)        
  Lymph node metastasis                                                        0.026
   Absent                 507 (60.7)         427 (59.2)       80 (70.2)        
   Present                328 (39.3)         294 (40.8)       34 (29.8)        
  ER                                                                           \<0.001
   Negative               266 (31.9)         259 (35.9)       7 (6.1)          
   Positive               569 (68.1)         462 (64.1)       107 (93.9)       
  PR                                                                           \<0.001
   Negative               366 (43.8)         347 (48.1)       19 (16.7)        
   Positive               469 (56.2)         374 (51.9)       95 (83.3)        
  HER-2                                                                        \<0.001
   Negative               672 (80.5)         565 (78.4)       107 (93.9)       
   Positive               163 (19.5)         156 (21.6)       7 (6.1)          
  Ki-67 LI                                                                     \<0.001
   ≤14                    501 (60.0)         409 (56.7)       92 (80.7)        
   \>14                   334 (40.0)         312 (43.3)       22 (19.3)        
  Molecular type                                                               \<0.001
   Luminal A              389 (46.6)         303 (42.0)       86 (75.4)        
   Luminal B              191 (22.9)         169 (23.4)       22 (19.3)        
   HER-2                  72 (8.6)           71 (9.8)         1 (0.9)          
   TNBC                   183 (21.9)         178 (24.7)       5 (4.4)          

IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; LI, labeling index; HER-2, human epidermal growth factor receptor-2; TNBC, triple-negative breast cancer.

###### Expressions of Sarcosine Metabolism-Related Proteins in Normal Breast Tissue and ILC

![](ymj-56-598-i004)

  Parameters                     Total, n=114 (%)   Normal tissue, n=30 (%)   ILC         *p* value^†^           
  ------------------------------ ------------------ ------------------------- ----------- -------------- ------- ---------
  GNMT                                                                                                   0.349   0.345
   Negative                      107 (93.9)         30 (100.0)                95 (93.1)   12 (100.0)             
   Positive                      7 (6.1)            0 (0.0)                   7 (6.9)     0 (0.0)                
  SARDH                                                                                                  0.473   0.014
   Negative                      94 (82.5)          30 (100.0)                85 (83.3)   9 (75.0)               
   Positive                      20 (17.5)          0 (0.0)                   17 (16.7)   3 (25.0)               
  PIPOX                                                                                                  0.714   \<0.001
   Negative                      42 (36.8)          28 (93.3)                 37 (36.3)   5 (41.7)               
   Positive                      72 (63.2)          2 (6.7)                   65 (63.7)   7 (58.3)               
  Sarcosine metabolic type                                                                               0.829   \<0.001
   High sarcosine type           1 (0.9)            0 (0.0)                   1 (1.0)     0 (0.0)                
   Intermediate sarcosine type   6 (5.3)            0 (0.0)                   6 (5.9)     0 (0.0)                
   Low sarcosine type            70 (61.4)          2 (6.7)                   62 (60.8)   8 (66.7)               
   Null type                     37 (32.5)          28 (93.3)                 33 (32.4)   4 (33.3)               

ILC, invasive lobular carcinoma; GNMT, glycine *N*-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase.

^\*^Compared between classic type and pleomorphic type.

^†^Compared between normal tissue and ILC.

###### Expressions of Sarcosine Metabolism-Related Proteins in IDC and ILC

![](ymj-56-598-i005)

  Parameters   Total, n=835 (%)   Normal tissue, n=30 (%)   IDC, n=721 (%)   ILC, n=114 (%)   *p* value
  ------------ ------------------ ------------------------- ---------------- ---------------- -----------
  GNMT                                                                                        0.231
   Negative    771 (92.3)         30 (100.0)                664 (92.1)       107 (93.9)       
   Positive    64 (7.7)           0 (0.0)                   57 (7.9)         7 (6.1)          
  SARDH                                                                                       0.045
   Negative    691 (82.8)         30 (100.0)                597 (82.8)       94 (82.5)        
   Positive    144 (17.2)         0 (0.0)                   124 (17.2)       20 (17.5)        
  PIPOX                                                                                       \<0.001
   Negative    612 (73.3)         28 (93.3)                 570 (79.1)       42 (36.8)        
   Positive    223 (26.7)         2 (6.7)                   151 (20.9)       72 (63.2)        

IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; GNMT, glycine *N*-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase.

###### Expressions of Sarcosine Metabolism-Related Proteins in ILC and Luminal-Type IDC

![](ymj-56-598-i006)

  Parameters   Total, n=586 (%)   IDC, luminal type, n=472 (%)   ILC, n=114 (%)   *p* value
  ------------ ------------------ ------------------------------ ---------------- -----------
  GNMT                                                                            0.228
   Negative    533 (91.0)         426 (90.3)                     107 (93.9)       
   Positive    53 (9.0)           46 (9.7)                       7 (6.1)          
  SARDH                                                                           0.923
   Negative    485 (82.8)         391 (82.8)                     94 (82.5)        
   Positive    101 (17.2)         81 (17.2)                      20 (17.5)        
  PIPOX                                                                           \<0.001
   Negative    410 (70.0)         368 (78.0)                     42 (36.8)        
   Positive    176 (30.0)         104 (22.0)                     72 (63.2)        

IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; GNMT, glycine *N*-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase.

###### Comparison of Sarcosine Metabolic Phenotypes between IDC and ILC

![](ymj-56-598-i007)

  Metabolic phenotypes       Total, n=835 (%)   Normal tissue, n=30 (%)   IDC, n=721 (%)   ILC, n=114 (%)   *p* value
  -------------------------- ------------------ ------------------------- ---------------- ---------------- -----------
  Sarcosine metabolic type                                                                                  \<0.001
   High sarcosine type       37 (4.4)           0 (0.0)                   36 (5.0)         1 (0.9)          
   Intermediate type         27 (3.2)           0 (0.0)                   21 (2.9)         6 (5.3)          
   Low sarcosine type        289 (34.6)         2 (6.7)                   219 (30.4)       70 (61.4)        
   Null type                 482 (57.7)         28 (93.3)                 445 (61.7)       37 (32.5)        

IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.

###### Comparison of Sarcosine Metabolic Phenotypes between Luminal-Type IDC and ILC

![](ymj-56-598-i008)

  Metabolic phenotypes           Total, n=586 (%)   IDC, luminal type, n=472 (%)   ILC, n=114 (%)   *p* value
  ------------------------------ ------------------ ------------------------------ ---------------- -----------
  Sarcosine metabolic type                                                                          \<0.001
   High sarcosine type           29 (4.9)           28 (5.9)                       1 (0.9)          
   Intermediate sarcosine type   24 (4.1)           18 (3.8)                       6 (5.3)          
   Low sarcosine type            217 (37.0)         147 (31.1)                     70 (61.4)        
   Null type                     316 (53.9)         279 (59.1)                     37 (32.5)        

IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.

###### Univariate Analysis by Log-Rank Test of the Impact of Sarcosine Metabolism-Related Protein Expression in Invasive Lobular Carcinoma on Disease-Free Survival and Overall Survival Times

![](ymj-56-598-i009)

  Parameters   Disease-free survival   Overall survival                   
  ------------ ----------------------- ------------------ --------------- -------
  GNMT                                 N/A                                N/A
   Negative    N/A                                        N/A             
   Positive    N/A                                        N/A             
  SARDH                                N/A                                0.538
   Negative    N/A                                        163 (157-169)   
   Positive    N/A                                        91 (83-98)      
  PIPOX                                0.941                              N/A
   Negative    164 (156-171)                              N/A             
   Positive    93 (89-96)                                 N/A             

GNMT, glycine *N*-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase; CI, confidence interval; N/A, not applicable.
